Impact of Diabetes Mellitus on Percutaneous Revascularization (CAVEAT-I)
Glenn N. Levine(American College of Cardiology), Robert M. Califf(Duke University), Alice K. Jacobs(Boston Medical Center), Patrick L. Whitlow(Cleveland Clinic), Gordon Keeler(Boston University), Eric J. Topol(Scripps Research Institute), Lisa G. Berdan(Boston University), Fred Leya(Boston University)
Cited by 55
Related Papers
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
|New England Journal of Medicine|2011|9.4k
Long COVID: major findings, mechanisms and recommendations
|Nature Reviews Microbiology|2023|4k
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
|Journal of the American College of Cardiology|2014|3.6k
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
|Circulation|2011|3.3k
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS
|European Heart Journal|2017|3k